PI3K at the crossroads of tumor angiogenesis signaling pathways

Area of Science:

• Oncology
• Cancer Biology
• Molecular Medicine

Background:

• Tumor growth necessitates new blood vessels (angiogenesis), making antiangiogenic therapy a key cancer treatment strategy.
• Current antiangiogenic therapies primarily target vascular endothelial growth factor (VEGF), but face limitations due to resistance and low response rates.
• Phosphoinositide 3-kinases (PI3Ks) are crucial signaling molecules involved in cell growth, survival, and metabolism, playing significant roles in both normal biology and cancer.

Purpose of the Study:

• To explore the role of the PI3K signaling pathway in tumor angiogenesis.
• To understand the diverse vascular responses to PI3K inhibition in the tumor microenvironment.
• To identify strategies for improving the efficacy of anti-cancer agents targeting PI3K.

Main Methods:

• Review of literature on PI3K signaling in angiogenesis and cancer.
• Analysis of the influence of the PI3K axis on angiogenesis across different cellular compartments.
• Summary of varied vascular responses observed upon PI3K inhibition.

Main Results:

• Class I PI3Ks are central to proangiogenic signals and influence endothelial cell (EC) functions, including growth, survival, and motility.
• PI3K signaling has complex, pleiotropic roles within the tumor microenvironment, impacting ECs directly.
• Inhibition of PI3K signaling elicits diverse vascular responses, highlighting pathway complexity.

Conclusions:

• Targeting the PI3K pathway offers a potential strategy to overcome resistance to current antiangiogenic therapies.
• The use of isoform-selective PI3K inhibitors may provide more precise targeting.
• Adjusting dosing strategies, potentially below maximum tolerated dose, alongside isoform selectivity, could enhance clinical outcomes for PI3K-targeted anticancer agents.